• 목록
• 답변
• 글쓰기

릴게임강시 80.rmq138.top 바로가기 황금성게임다운

바다이야기주소알라딘예시오션파라다이스시즌7야마토 빠칭코

릴게임강시 1.rmq138.top 황금성게임다운

릴게임강시 53.rmq138.top 황금성게임다운

릴게임강시 62.rmq138.top 황금성게임다운

릴게임강시 76.rmq138.top 황금성게임다운

릴게임강시 29.rmq138.top 황금성게임다운

릴게임강시 73.rmq138.top 황금성게임다운

릴게임강시 75.rmq138.top 황금성게임다운

릴게임강시 20.rmq138.top 황금성게임다운

릴게임강시 40.rmq138.top 황금성게임다운

릴게임강시 11.rmq138.top 황금성게임다운

포커게임사이트 오션파라다이스시즌7 야마토 빠칭코 황금성다운 카지노 슬롯 게임 추천 황금성하는곳 메이저 슬롯사이트 바다이야기예시종료 파칭코사이트 오션파라다이스 바다이야기꽁머니환전윈윈 백경다운로드 황금포커성 릴게임매장 중고게임기 매매 일본 파칭코 릴게임꽁머니 오션파라다이스 예시 파라다이스오션 모바일릴게임 종류 릴게임황금포카성 파칭코하는법 야마토3게임 다운로드 하기 종합릴게임 바다이야기 게임장 바다이야기pc버전다운 모바일야마토게임 무료슬롯버프 릴게임 공략법 오리지날바다 신천지게임하는곳 인터넷백경 키지노릴게임 바다이야기확률 바다이야기게임2018 바다이야기pc 파칭코슬롯 황금성게임종류 야마토2게임하기 야마토카지노 야마토5게임기 프라그마틱 슬롯 무료체험 카카오야마토먹튀 유희왕황금성 황금성배당 팡멀티릴게임 바다이야기디시 Pg 소프트 무료 체험 슬롯 무료스핀구매 알라딘먹튀 릴게임꽁머니 알라딘게임 릴게임골드몽릴게임 우주전함야마토2199 야마토2 신천지사이트 바다이야기게임 릴게임 정보 카카오바다이야기 황금성게임다운 오션파라 다이스게임다운로드 황금성3하는곳 바다이야기 환전 가능 황금성2 릴게임황금포카성 오션파다라이스 다운로드 없습니다. 야마토게임기 매장판황금성 모바일파칭코 바다게임 야마토3게임다운로드 릴게임백경 프라그마틱환수율 릴게임팡게임 야먀토5 슬롯머신 종류 손오공릴게임예시 슬롯머신 기계 구입 한국파친코 손오공게임온라인 오션파라다이스시즌7 일본 파칭코 바다 슬롯 먹튀 호게임 슬롯머신 777 릴게임손오공게임 슬롯나라무료 바다이야기5만 스톰게임 안전 검증 릴게임 최신야마토게임 다빈치릴게임먹튀 씨엔조이 릴게임 오션파라다이스 온라인 오션파라다이스7하는곳 슬롯머신 하는법 야마토2게임 황금성게임설명 황금성 게임 장주소 카지노 슬롯머신 잭팟 온라인슬롯 배팅법 스톰게임 바다이야기 모바일게임 황금성게임앱 황금성게임종류 릴게임 백경 게임황금성 알라딘게임예시 바다이야기릴게임사이트추천및안내 온라인 릴게임 손오공 오션파다라이스 다운로드 백경게임다운로드 릴게임오션파라다이스 백경게임공략방법 슬롯 무료스핀구매 바다이야기 도박 바다이야기 사이트 슬롯머신 영어로 사이트추천 황금성다운로드 바다이야기 릴게임 사이트 추천 및 안내 카카오야마토 양귀비 릴게임 신천지릴게임장주소 This article was released as Pharm Edaily Premium Content on July 25, 2025, at 8:30 AM.


[Seok Ji-hoen, Edaily reporter] Shares of Selbion gained for a second straight day Wednesday as investors responded positively to the company’s combination trial strategy involving global pharmaceutical giant Merck(MSD). Dongkook Life Science also surged following news of a 100% 학자금 저금리 전환 방법 stock dividend, while Ildong Pharmaceutical ended the session up more than 7% on renewed expectations for its oral GLP-1 drug candidate.
“Potential to Outperform Lekraza”
Accordin 하나은행닥터클럽 g to KG Zeroin’s MP Doctor (formerly Market Point), shares of Selbion closed at 27,450 won, up 1,950 won or 7.65%. The stock rally followed a recent interview in which CEO Kwon Kim unveiled the compan 무주택자 대출 y’s plan to co-develop a prostate cancer treatment in combination with Merck’s immunotherapy Keytruda.



Selbion stock performance (Image captured from Nav cofix 기준금리 er Finance)



PharmEdaily had published a paywalled interview with Kim on July 21 under the headline “Selbion CEO: ‘Keytruda Combo Could Beat Lekraza’.” The 앤캐쉬 article was made publicly available on July 23. Selbion’s shares rose 5.6% that day and continued their climb on Wednesday.

In the interview, Kim said, “If our proprietary radiopharmaceutical Lu-177-DGUL proves successful in combination with Keytruda, it has the potential to outperform Lekraza from Yuhan Corp. We are currently in positive talks with Merck.”
Selbion has applied for a Phase 1 clinical trial in Korea for the combination therapy. A separate Phase 2 monotherapy trial has completed patient dosing, with topline data expected in the third quarter. The company plans to apply for conditional approval later this year and is targeting a domestic launch in the first half of 2026. Industry analysts forecast the treatment could generate up to 20 billion won ($15 million) in domestic revenue once on the market.
What sets Lu-177-DGUL apart is its ability to convert prostate cancerㅡa so-called “cold tumor” with poor immune responseㅡinto a “hot tumor,” thereby enhancing the efficacy of immunotherapies such as Keytruda. This could allow the therapy to overcome limitations seen with Keytruda monotherapy in prostate cancer.
According to market research, the global prostate cancer treatment market is expected to grow from 21 trillion won ($15.2 billion) in 2022 to 40 trillion won ($29 billion) by 2030. “We are also in talks with other global pharmaceutical companies regarding licensing and co-development,” Kim added. “These discussions will accelerate our monetization and pipeline expansion as Lu-177-DGUL approaches commercialization.”
When asked about the stock move, a Selbion spokesperson told Edaily, “There is no specific development within the company to share at this time.”
100% Stock Dividend Boosts Dongkook Life Science
Shares of contrast agent specialist Dongkook Life Science closed at 9,660 won, up 620 won or 6.86%, after the company announced a 100% stock dividend.
Dongkook’s board of directors approved the plan to issue one new share for each existing common share. The company said the move aims to expand liquidity and reinforce shareholder-friendly policies, backed by strong fundamentals.



Dongkook Life Science stock performance (Image captured from Naver Finance)



As a result, Dongkook’s total number of outstanding shares will double from 15.99 million to 31.98 million. The record date for the stock dividend is Aug. 8, with listing of the new shares scheduled for Aug. 29. Capital stock will rise from 8 billion won to 16 billion won.

“The purpose of this decision is to maximize shareholder value and broaden the investor base,” a company spokesperson said. Since its establishment in 2017, Dongkook has posted average annual growth rates of 15.6% in revenue and 14.5% in operating profit.
The company operates a fully integrated vertical manufacturing system for contrast agents and is currently investing in new business areas such as an MRI contrast agent, a tripling of capacity at its Anseong plant, and contract manufacturing (CMO). Sales of the company’s latest contrast agent, Mediray, have been strong since its launch in late 2024, supporting further earnings momentum.
“We don’t have any additional comment regarding the stock movement,” a company official said. “The dividend is purely aimed at enhancing shareholder returns and stock liquidity.”
“Competitive With Global Candidates”
Shares of Ildong Pharmaceutical closed at 22,150 won, up 1,550 won or 7.52%, amid growing optimism over its oral GLP-1 obesity treatment candidate.
According to a July 24 report by IV Research, Ildong’s oral small-molecule GLP-1 drug ID110521156 has produced clinical data comparable to global competitors and could warrant a revaluation of the company’s pipeline assets.



Ildong Pharmaceutical stock performance (Image captured from Naver Finance)



The report noted that no clear winner has emerged between peptide-based and small-molecule oral GLP-1 drugs. While peptides currently dominate, small molecules offer advantages such as better tissue permeability, higher bioavailability, and lower manufacturing costs.

Eli Lilly’s small-molecule GLP-1 candidate Orforglipron showed 7.9% weight loss in its Phase 3 ACHIEVE-1 trial, but up to 8% of participants discontinued due to gastrointestinal issues. Pfizer, meanwhile, halted development of Lotiglipron and Danuglipron due to liver toxicity concerns.
By contrast, Ildong’s ID110521156 showed strong safety and efficacy in its domestic Phase 1 trial. The low-dose (50mg) group saw average weight loss of 5.50%, and the mid-dose (100mg) group recorded 6.89% (max 11.9%), versus 2.72% in the placebo group. No liver toxicity or treatment-related discontinuations were reported.
“These results are competitive with Orforglipron, and the upcoming topline data for the high-dose (200mg) cohort, expected in August?September 2025, will be a key catalyst,” IV Research stated. The trial was designed with input from a leading global obesity drug developer, and licensing talks are reportedly underway.
On the financial front, IV Research noted that Ildong recorded net losses from 2020 due to heavy R&D investment, but returned to operating profit in 2024. The company’s R&D expenses dropped from 127.6 billion won in 2022 (20% of revenue) to 46.3 billion won in 2024 (7.5%).
“With clinical progress becoming visible, now is the time to reflect the value of the company’s GLP-1 pipeline in its market capitalization,” the report concluded.
When asked for comment, an Ildong official told Edaily, “There’s no specific internal development that we can share regarding the stock price movement.”
석지헌 (cake@edaily.co.kr)